Allogene Therapeutics, Inc. (ALLO) Dividend History

Company News

• Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

  Allogene Therapeutics presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma, showing promising results with a 31% confirmed response rate and durable responses in heavily pretreated patients.

  GlobeNewswire Inc.
• CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

  The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

  GlobeNewswire Inc.

  Featured Companies: ACLX DTIL IPSC KYTX RNAC SANA
• Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

  The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.

  Benzinga

  Featured Companies: CNTX ERAS ONCY RXRX
• Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

  The gene therapy market is experiencing significant growth, with over 180 companies actively developing more than 200 gene therapies. This dynamic landscape highlights the increasing investment and innovation in the sector, promising new treatment options for various diseases.

  GlobeNewswire Inc.

  Featured Companies: ADVM KYTX RARE RCKT
• Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%

  The gene editing therapeutics market is expected to grow significantly, reaching $1 billion by 2029 with a CAGR of 147%. Key drivers include the increasing prevalence of chronic and rare genetic diseases, as well as the need for precision medicine.

  GlobeNewswire Inc.

  Featured Companies: BEAM CRBU CRSP DTIL EDIT NTLA SGMO VOR VRTX